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The effects on breast cancer mortality seen after 16 years of 
biennial screening of younger women are assessed in this 
prospective cohort study. Since 1975 some 13,500 women, aged 
35—49 in 1975, were invited to  participate in the Nijmegen 
screening programme comprising a mammographic examina­
tion every 2 years. By the end of 1990, 75 women had died of 
breast cancer out of th e  332 cases diagnosed after the start of 
the screening project. Women from the same birth cohort, 
living in Arnhem, a neighbouring city with a comparable 
population and without a  screening project, were used as 
controls. In this city, 74 breast cancer deaths out of 284 cases 
occurred during the same period. In Nijmegen, after 16 years of 
follow-up, breast cancer mortality showed a non-significant 
reduction of 6% (95% confidence interval: 32% reduction, 29% 
excess). In the relevant period, after a time lag of 10 years from 
the start of the programme, this reduction rose to 20% (95% 
confidence interval: 48% reduction, 23% excess). No reduction 
in breast cancer mortality was observed in the first decade of 
screening. For a later period, a shift towards a reduction 
emerges, but the data are as yet inconclusive.
© 1995 Wiley-L iss, In c.
Up until now the benefit of periodic breast cancer screening, 
with modern mammography, of women under 50 years of age 
has been controversial (Beral, 1993; Fletcher et al, 1993; 
Sickles and Kopans, 1993; Jatoi and Baum, 1993; Harris, 1994).
In the oldest trial, the Health Insurance Plan (HIP) study 
from the early sixties, with 4 annual mammographic examina­
tions combined with physical examination, positive results 
were only observed after a long follow-up of 8 years (Shapiro et 
al, 1988). Since the HIP study, the quality of mammography 
has improved considerably, facilitating the detection of more 
tumours in an early stage of development before they have 
reached an incurable stage. Modern mammography therefore 
might be expected to produce a stronger effect on breast- 
cancer mortality. However, this expectation is lowered by the 
fact that in most ongoing trials the screening interval is at least 
2 years, instead of 1 year as in the HIP trial. Moreover, 
mammography is commonly used as the only screening modal­
ity, whereas the HIP study also included palpation. In addi­
tion, the prognosis of today’s breast cancer patients may 
already have improved to such an extent (e.g., due to early 
self-detection and a greater cautiousness regarding suspect 
lesions in the breast), that early detection by population 
screening might have a lower effect than anticipated.
So far, the results of ongoing trials for women under age 50 
have been inconclusive (Andersson et a l, 1988; Roberts et al., 
1990; Frisell et al.f 1991; Miller et al., 1992). There appears to 
be little evidence of benefit, at least in the first 10 years after 
the initial screening examination. A recent analysis of the 
combined Swedish data, a pooling of 5 studies with a screening 
interval of 1.5 to 2 years, has shown a non-significant benefit of 
13% after a follow-up of 7 to 12 years (Nystrom et al., 1993). 
This study suggests that, in this age group, a potential 
beneficial effect cannot be expected in the first decade after 
the start of screening.
In our study, breast cancer mortality in the study population 
of Nijmegen, aged 35 to 49 at the start of the first screening 
round in 1975 (13,500 women), has been analysed after 16
years of follow-up. The results are compared with those of the 
neighbouring city of Arnhem.
STUDY POPULATION AND METHODS
In the city of Nijmegen (150,000 inhabitants) a population- 
based biennial screening programme for breast cancer was set 
up in 1975 (Pceters et al., 1989a). Single-view mammography 
was carried out as the only screening procedure every 2 years. 
In the first screening round, all women born in the period 
1910-1939 were invited. The present study is restricted to 
women born in 1925-1939, aged under 50 at January 1, 1975. 
For the “date of entry” into the study the date of first invitation 
was taken. In the present analysis, women who moved into the 
area of Nijmegen were also included. This immigration was 
approximately 1% yearly. The end of the study period was set 
as the date of death, the date of moving out of Nijmegen, or the 
end of 1990. By this time 8 screening rounds had been carried 
out. The attendance rate was 87% in the first screening round 
and stabilized at about 65% after the fourth round.
The control group consists of women of the city of Arnhem. 
This neighbouring city, 15 miles distant from Nijmegen, also 
has some 150,000 inhabitants. The date of entry into the study 
for a woman from the control group was considered to he the 
date midway through the first screening round in Nijmegen, i.e. 
January 1, 1976, or, alternatively, the date when she moved 
into Arnhem. The follow-up period ended upon death, upon 
moving out of the city or by the end of 1990, Because no 
information on an individual level was available, mid-year 
estimates for woman-years at risk for birth cohort 1925-1939 
were calculated from the official census statistics, published 
yearly by the Dutch Central Bureau of Statistics.
Information about breast cancer deaths subsequent to 
diagnosis after entry into the study was obtained by a review of 
the medical files of the deceased patients.
Since 1975, data on all Nijmegen patients diagnosed as 
having breast cancer in cither of the Nijmegen hospitals have 
been carefully recorded by the local cancer registry of the 
Departments of Diagnostic Radiology and Pathology, resulting 
in a number of 332 patients diagnosed with primary breast 
cancer between entry into the study and the end of 1990. The 
list of all patients diagnosed up to the end of 1988 was 
submitted to the local registrar’s office for vital status assess­
ment at December 31, 1988. Since the beginning of 1989 the 
local registrar’s office has supplied us weekly with all the dates 
of migrations and deaths among Nijmegen women born before 
1940. All clinical information concerning the dead patients was
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gathered to ascertain the cause of death, i.e., breast cancer or 
other. Breast cancer was considered to be the underlying cause 
of death when distant metastases had been reported prior to 
death and competing causes of death could be ruled out.
For the control population of Arnhem, the Carcinoma 
Working Group composed a list of 284 patients with primary 
breast cancer diagnosed since 1976. The same procedure and 
criteria for assessing the cause of death were applied in both 
cities.
The breast cancer mortality rate ratio with 95% confidence 
interval of the Nijmegen versus Arnhem study populations was 
calculated.
non-significant reduction in 
was found (relative risk =
0.52-1.23).
breast-cancer mortality 
0.80; 95% confidence
of 20%
interval
RESULTS
From the start of the screening project until the end of 1990, 
a total of 332 breast cancer patients, including 38 with ductal 
carcinomas in situ, were diagnosed in Nijmegen. Of these 
cancers, 38% were detected by screening, 36% appeared in the 
interval between screenings and 25% were found in women 
who had been invited for screening but had not responded to 
the last invitation (Table I). By the end of 1990,29 patients had 
left Nijmegen and 82 had died. In Arnhem, in the same birth 
cohort and calendar period, 284 patients, of whom only 4 were 
known to have intraductal carcinoma, were diagnosed. During 
the study period 14 patients had moved away from Arnhem 
and 84 had died. For 3 Arnhem patients (who died in 1977, 
1982 and 1986) the cause of death could not be assessed. 
Breast cancer was considered to be the underlying cause of 
death of 75 patients in Nijmegen and 74 patients in Arnhem. 
Three-quarters of the deaths from breast cancer in Nijmegen 
occurred in women whose tumour had been diagnosed in the 
interval between screenings or in women who had not re­
sponded to the last screening invitation. Nevertheless, as many 
as one-quarter of the deaths occurred in women whose 
carcinoma had been detected al screening. Compared with 
Arnhem, Nijmegen showed a non-signiiicant 6% decrease in 
the cumulative number of breast cancer deaths (cumulative 
relative risk = 0.94; 95% confidence interval 0,68-1.29).
Figure 1 shows the cumulative breast-cancer mortality in the 
2 cities for patients diagnosed after the start of the screening 
project in Nijmegen. Previous studies have suggested that no 
eiiect of screening can be expected in the first 10 years after 
initiation of screening; we t icrefore considered the breast- 
cancer mortality rate ratio for 3 time intervals (1976-1980, 
1981-1985,1986-1990) specified separately in Table II, After a 
time lag of 10 years from the start of the programme, a
DISCUSSION
This study addresses the issue of long-term breast-cancer 
mortality in young women who had the opportunity of mammo- 
graphic screening once every 2 years.
Due to the non-randomized design of the Nijmegen pro­
gramme, special attention was given to potential sources ot 
bias. Of major concern was the comparability of the popula­
tions in the 2 cities with respect to risk of breast-cancer death. 
To evaluate comparability, population mortality rates of breast 
cancer in the pre-screening period in both cities were assessed. 
In the period 1970-1974, Nijmegen appears to have had a 
lower mortality in the 35-64 age group (rate ratio = 0 .68; 95% 
confidence interval 0.48-0.96) (Hendriks, 1982). However, this 
apparently lower risk for breast-cancer deatli does not persist 
in the period 1975-1979, the first years of the programme 
(Peelers et a I, 1989/?). Taking these figures into consideration, 
no unambiguous conclusion can be drawn regarding the 
“baseline” differences in breast-cancer mortality in the eight­
ies for cases diagnosed after the start of the screening project. 
Any diifercncc in breast cancer mortality between the 2 cities 
in favour of Nijmegen which is not due to intervention 
diminishes the reduction attributable to screening.
In the whole 16-year period of follow-up (1975-1990, that is 
from the start of screening to the end of follow-up) an 8% 
excess of breast-cancer cases was observed in Nijmegen. 
Higher incidence is to be expected from any screening pro­
gramme for breast cancer because of the advanced detection 
through screening and increasing incidence with age (Boer ct 
al, 1994). In younger women the detection of many ductal 
carcinomas in situ (D O S ) may also contribute to an increase in 
incidence. In the present study 22% (N = 28) of the screen- 
detected cancers are DCIS. The likelihood of these DC IS 
progressing to clinical disease in the absence of screening is 
unknown. In our study, part of the excess may also be ascribed 
to an under-recording of breast-cancer cases in the first years 
in Arnhem. The Carcinoma Working Group, Arnhem, has 
been operative since 1979. In the 3-year period prior to 1979 
the breast-cancer incidence rate in the younger age-groups was 
23% less than might have been expected on the basis of the 
incidence rates in the overall Dutch population as obtained 
from the Central Bureau of Statistics. Between 1979 and 1988 
the incidence rate in Arnhem was the same as that in the total
TAIlLti I - CUMULATIVI’: IMHAST-C'ANŒK INCIDENCE AND MORTALITY RATH IN NIJMEGEN ANI) ARNI I EM 
AMONG PAT! I'NTS FROM HIRTII COHORT IU25-IW9 DIAGNOSED AFTER THE START OF THE SCREEN INC»
PROJECT IN NIJMEGEN UNTILTIIEHND OF 1 «
Number of primary breast cancers 
Screen-detected 
Interval
Non-participant
Moved away from the city
Died from causes of all kinds
Died from breast cancer 
Screen-detected 
Interval
Non-participant
Woman-years
Breast-cancer mortality rate 
(per l()t),000 woman-years)
Rate ratio 
95% Confidence interval
Nijmegen, 
¡»fier entry
332
128 (38%) 
119 (36%) 
85 (25%)
29
82
166,307
45.1
Arnhem, after 
January I, I‘>76
284
14
84
74
154,103
48.0
0.94
0.68-1.29
810 PEER ETAL
Dutch population. A random under-reporting of 23% in the 
first 3 years in Arnhem would have yielded 4 more breast 
cancer deaths, increasing the cumulative breast cancer mortal­
ity reduction from 6% to 11% and, in the post-10-year 
observation period 1986-1990, from 20% to 21%.
Determination of the underlying cause of death can be 
subject to a (differential) misclassification. In the breast-
C u m u la tiv o  n u m b e r  o f  b r e a s t  c a n c e r  d e a th «
C a le n d a r  y e a r
F ig u r e  1 -  Cumulative breast cancer mortality rate in Nijmegen
(------) and Arnhem (........ ) among patients from birth cohort
1925-1939 diagnosed after the start of the screening project in 
Nijmegen.
cancer patients of this younger age group, however, compctin 
causes of death were involved only in a minor proportion of th< 
deceased patients. In the overview of the Swedish randomize« 
trials the mortality reduction in the whole study populatioi 
was similar, irrespective of the end-point used Tor cvaluatioi 
(Le,, “breast cancer as underlying cause of death” or “breas 
cancer present at death” ) (Nystrom et a i,  1993).
The deaths occurring during the first years of a screening 
programme will mainly concern patients whose disease was 
already at an advanced stage at the time of diagnosis. It is thus 
reasonable to assume that the effect of screening for breast 
cancer is delayed in any age group. One may expect, however, a 
longer delay for younger women because of (I.) the better 
relative survival of younger patients with breast cancer (Adami 
et a i, 1986) and (2) an apparently longer lead time of cases of 
DCIS which are detected more frequently in this age group, in 
the more relevant observation period, beginning one decade 
after the start of the programme, Le. the period 1986-1.990, our 
study showed a promising 20%, though still non-significant 
reduction in mortality. One could advance the idea that this 
reduction is the effect of the screening of those women who 
passed the age of 50 during the observation period, but this 
supposition is not supported by the observations in women of 
birth cohort 1925-1929 (aged 45 to 49 at the start), among 
whom no mortality reduction during the period 1986-1990 was
observed,
Taking into account ail the available information and 
possible sources of bias, we conclude that biennial mammo- 
graphic screening of women under the age of 50 in Nijmegen 
has not resulted in a reduction in breast-canccr mortality 
during the first decade. For a later period, a shift towards a 
reduction emerges, but the data are as yel inconclusive.
All women in the 1925-1939 birth cohort have now passed 
the age of 50 and they will be screened biennially as part of a 
nation-wide screening programme, which includes Arnhem as 
well. If longer follow-up reveals that the reduction in breast 
cancer mortality continues to be present, this could be the 
eifect of screening the younger age group in Nijmegen.
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TABLE II -  BREAST CANCER MORTALITY IN NIJMEGEN AND ARNHEM AMONG PATIENTS DIAGNOSED 
AFTER THE STARI' OF THE SCREENING PROJECT IN NIJMEGEN ACCORDING TO CALENDAR PERIOD AND
BIRTH COHORT
Period Birthcohort
Woman'-years lireasl-canctTdeaths
Nijmegen Arnhem Nijmegen Arnhem
1976-•1980 1935-1939 18,742 16,610 2 (1
1930-1934 19,062 17,389 4 5
1925-1929 18,962 18,811 6 3
1925-1939 56,766 52,810 12 8
1981-■1985 1935-1939 18,720 16,536 8 0
1930-1934 18,917 16,987 8 7
1925-1929 18,459 18,225 8 12
1925-1939 56,096 51,751 24 21
1986-■ 1990 1935-1939 17,937 16,120 10 17
1930-1934 18,026 16,237 16 16
1925-1929 17,482 17,186 13 12
1925-1939 53,445 49,542 39 45
Rate nil io
1.40 (0.57-3.40)
1.05 (0.59-1.89)
0.80 (0.52-1,23)
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